Multiple Myeloma
2020 Year in Review - Multiple Myeloma | February 1, 2021
Comparing consolidation treatment with bortezomib + lenalidomide + dexamethasone (VRD) followed by lenalidomide maintenance with lenalidomide maintenance alone, the former approach was superior regarding progression-free survival (PFS) and myeloma response in patients with newly diagnosed multiple myeloma (MM) with an acceptable toxicity profile.
2020 Year in Review - Multiple Myeloma | February 1, 2021
This multicenter, retrospective, real-world study (GEM-POMCIDEX) was initiated to evaluate the effectiveness of the guidelines established by the Spanish Myeloma Group (PETHEMA) to treat appropriate patients with relapsed/refractory multiple myeloma (RRMM) with pomalidomide, cyclophosphamide, and dexamethasone (POMCIDEX).
2020 Year in Review - Multiple Myeloma | February 1, 2021
Poor response on subsequent therapies is typically seen in patients with relapsed/refractory multiple myeloma (RRMM) who have had 3 prior lines of therapy with immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies. In addition, challenges for future treatment options are presented.
2020 Year in Review - Multiple Myeloma | February 1, 2021
Recent studies have illustrated complete response (CR) rates >50% for transplant-eligible patients with multiple myeloma (MM) treated with optimized induction followed by high-dose therapy (HDT) and autologous stem-cell transplantation (ASCT). However, many patients relapse early. Patients who relapse are generally thought to have very low survival rates.
2020 Year in Review - Multiple Myeloma | February 1, 2021
According to data from the phase 2 FORTE trial, 3 different techniques were analyzed and compared to characterize minimal residual disease (MRD), including positron emission tomography/computed tomography (PET/CT), multiparameter flow cytometry (MFC), and next-generation sequencing (NGS).
August 2020 Vol 11, No 8 | August 5, 2020
The combination of carfilzomib with lenalidomide and dexamethasone (KRd) as induction therapy has failed to improve outcomes in newly diagnosed multiple myeloma compared with bortezomib, lenalidomide, and dexamethasone (VRd).
August 2020 Vol 11, No 8 | August 5, 2020
Cellular therapy is quickly becoming an attractive option for heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). According to data presented at the ASCO20 Virtual Scientific Program, a pair of chimeric antigen receptor (CAR) T-cell products have generated impressive rates of response that appear to be sustainable as well.
June 2020 Vol 11, No 6 | June 3, 2020
In no arena is fear more relevant than in the realm of cancer survivorship. This article will help you to identify and address fear of recurrence for your patients.
April 2020 Vol 11, No 4 | April 9, 2020
When elotuzumab was given in
combination with pomalidomide,
bortezomib, and dexamethasone
(elo-PVD), patients with
multiple myeloma refractory to prior
treatment demonstrated encouraging responses,
according to data from a phase 2
trial presented at the 2019 ASH Annual
Meeting by Andrew Yee, MD, from Massachusetts
General Hospital Cancer
Center in Boston.
April 2020 Vol 11, No 4 | April 9, 2020
In patients with multiple myeloma who were pomalidomide
naive and refractory to lenalidomide, an alloral
combination of selinexor, pomalidomide, and
dexamethasone (SPd) led to a median progression-free
survival (PFS) of 12.2 months and an overall response
rate (ORR) of 56%, with 19% of patients achieving very
good partial responses.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512